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bial regimen consisting of tigecycline plus extended-infusion imipenem/cilastatin (TIC) and
regimen of sulbactam plus imipenem/cilastatin (SIC) for patients with ventilator-associated
pneumonia and pneumonic bacteremia due to extensively drug-resistant (XDR) Acinetobacter
baumannii (Ab) isolates, and determine the correlation of results of in vitro tigecycline
eimipenem synergy test with clinical efficacy.
Methods: The comparative survey was conducted at a medical center in Taiwan in 2013. Pa-
tients comprising the TIC group (n Z 28) received tigecycline plus extended-infusionMedicine, Department of Emergency and Critical Care Medicine, Wan Fang Hospital, Taipei Medical
Rd, Wen-Shen District, Taipei 11696, Taiwan.
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TIC versus VAP due to XDR Acinetobacter baumannii 925tigecycline;
ventilator-associated
pneumoniaimipenem/cilastatin following unresponsiveness to 3-day sulbactameimipenem/cilastatin
therapy, and those in the SIC group (n Z 56) received sulbactameimipenem/cilastatin
throughout the course. Univariate and multivariate analyses were applied to explore 30-day
case-fatality independent predictors. Additionally, the checkerboard test and time-kill anal-
ysis were performed for the bloodstream XDR-Ab isolates from patients in the TIC group,
and molecular characterization was done for the bloodstream XDR-Ab strains of all patients.
Results: We found that the TIC scheme has a significant benefit on improving patients’ survival
status (the mortality rate of TIC and SIC group patients was 14.3% and 64.3%, respectively),
corresponding well with in vitro synergy or additivity results by the checkerboard test. Twenty
TIC group cases had monomicrobial XDR-Ab cultured from tracheal aspirates after 10 days of
tigecyclineeimipenem/cilastatin therapy, but none developed subsequent pneumonia. How-
ever, breakthrough primary Burkholderia cepacia (n Z 3) and Pseudomonas aeruginosa
(n Z 1) bacteremias were attributed to four TIC case fatalities. Shock, SIC regimen usage,
and development of breakthrough bacteremia were independent predictors of 30-day in-
hospital mortality.
Conclusion: Although the TIC regimen showed good efficacy, its value regarding managing XDR-
Ab ventilator-associated pneumonia bacteremia needs further evaluation.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Pneumonia acquired at the nosocomial setting is associated
with higher mortality rates than that of community origin.1
Of the etiologies implicated in nosocomial pneumonia (NP),
Acinetobacter baumannii (Ab) drew the most worldwide
concern in that its high potential of dissemination, and
bacteremia due to multidrug-resistant (MDR)-Ab have been
shown in association with a significantly high 30-day mor-
tality rate (range 29e43%).2,3 Previously, a number of re-
ports revealed that high nonsusceptible rates of nosocomial
Ab isolates against carbapenem agents were found inTai-
wan.4,5 During the past decade, Ko et al6 demonstrated
that meropenem at 0.5-fold of the minimum inhibitory
concentration (MIC) plus sulbactam (1.0  MIC) would
exhibit excellent bactericidal suppression on MDR-Ab for up
to 48 hours. This result provided a robust basis for the
scheme of antipseudomonal carbapenem plus sulbactam on
managing the MDR-Ab infections clinically. However, the
epidemic of MDR-Ab isolates conferring medium to high
resistance to this regimen had emerged in Taiwanese
intensive care units since 2000.7 In addition, a considerable
variability in pulmonary penetration ratios of meropenem
[i.e., concentration of epithelial lining fluid (ELF) to that of
plasma, ranging from 0.037 to 1.78],8 and the absolute
requirement of relatively high targets of meropenem
exposure in ELF for the patients with ventilator-associated
pneumonia (VAP), who often have significantly high resis-
tant burdens of Gram-negative bacteria (GNB; especially
when their meropenem MICs are 1.0 mg/mL) in pulmonary
tissue have been demonstrated recently.9 Owing to the
worsening resistance trend, combination therapies there-
fore have become an important option against the exten-
sively drug-resistant (XDR)-GNB pathogens nowadays.
Nevertheless, combination therapy was often prescribed
empirically without the support of in vitro synergy data, as
evidenced by the fact that the PubMed literaturedocumenting corroboration of results of in vitro synergism
of antibiotics on good clinical outcome remains scarce.10,11
The lack of correlation between different in vitro
methods in assessing the synergism of antimicrobial com-
binations is an arguable concern. Regarding the in vitro
methodologies evaluating drugedrug interaction, checker-
board titration analysis, which calculates the index by
comparing the MIC of combination regimen with each single
drug, and time-kill kinetic analysis, are two most widely
used modalities.12,13 Despite the fact that time-kill analysis
was considered to have an advantage of evaluating the
dynamic interaction of two or more agents, the checker-
board MIC test is still the most commonly used assay of
screening synergism.12 As the data of correlation between
in vitro interaction of dual antibiotics and real clinical
outcome are generally lacking, we conducted this
comparative study to assess the difference in clinical effi-
cacy between tigecycline plus extended-infusion imipe-
nem/cilastatin (TIC) and sulbactam plus imipenem/
cilastatin (SIC) against VAP bacteremia due to nosocomially
acquired XDR-Ab isolates in 2013. In addition, we also
investigated the correlation between the results of the
in vitro synergy test and the clinical outcome of patients in
the TIC group in this survey.Methods
Patient recruitment and evaluation
This study was prospectively conducted at Wan Fang Hos-
pital, a 732-bed medical center located in northern Taiwan.
Adult ( 18 years) patients with VAP who met the definition
of the United States Centers for Disease Control and Pre-
vention (new infiltrate, or consolidation on radiographic
evidence, consistent signs and symptoms, and associated
laboratory data),14 with cultures of tracheal aspirate and
926 S.-S. Jean et al.blood samples ( 2 sets, respectively) showing the Ab
complex of an identical resistance profile, were eligible as
candidates for investigation. VAP was diagnosed as NP
requiring the support of mechanical ventilation based on
the Centers for Disease Control and Prevention guidelines.
If isolates of the Ab complex from blood culture were
verified to be Ab species by the molecular method (see
following Discussion), the participants whose first VAP XDR-
Ab VAP bacteremia failed to respond to 3-day imipenem
(500 mg every 6 hours) plus sulbactam (1.5e2.0 g every 6
hours) were considered potential candidates for this study.
After written consent was obtained from all participants,
these cases (designated as the TIC group) were subse-
quently treated with standard-dose tigecycline with a 1-
hour infusion duration, plus imipenem/cilastatin with an
extended-duration (3 hours) infusion (daily dosage was
adjusted according to the patient’s creatinine clearance
rate) for a minimum of 10 days if feasible; the therapy
duration was based on the recommendation of the guide-
lines described previously.1 The written informed consent
contained special notes stating that tigecycline was an off-
label agent for treating VAP by the suggestion of the United
States Food and Drug Administration15 and was therefore
prescribed as the salvage therapy in our study. All TIC pa-
tients were enrolled from February 1, 2013 through
December 31, 2013. If the fungus was judged as the caus-
ative etiology of urinary tract or other (catheter, blood-
stream, etc.) infection entity, addition of appropriate
antifungal agent(s) was justified. Additionally, if a new
febrile episode, hemodynamic instability, or altered mental
status without plausible explanations developed during the
antibiotic therapy course, a new blood culture survey would
be performed if needed. The exclusion criteria were as
follows: (1) the bacteremic episode was not mono-
microbial, or had mixed genospecies or unidentified spe-
cies; (2) hypersensitivity to either antibiotic agent
evaluated; (3) presence of severe liver cirrhosis (> 9 points,
assessed using the ChildePugh score system), or severe
hepatic failure of any other etiology; (4) other than XDR-
Ab, the etiological microorganisms in the lower respira-
tory tract were not in vitro susceptible to tigecycline plus
imipenem/cilastatin. The clinical character-
isticsdincluding age, sex, underlying comorbidities and
Charlson index score,16 total leukocyte count, Acute Phys-
iology and Chronic Health Evaluation II score,17 Pitt
bacteremia score within 24 hours of the XDR-Ab bacter-
emia,18 clinical pulmonary infection score,19 and the ratio
of the patient’s arterial partial pressure of oxygen to the
fraction of inspiratory oxygen from the ventilator (PaO2/
FiO2) at the day of XDR-Ab bacteremia, as well as the Day
30 outcome (the day when XDR-Ab bacteremia happened
was counted as Day 1)dof the enrolled patients were
recorded in detail. Moreover, prior stay at any healthcare
setting (hospitalization  3 days, or nursing home resident)
prior to this admission, as well as the duration between
admission day and the date of acquiring XDR-Ab VAP
bacteremia were also recorded for each patient. The
follow-up microbiological assessment of suctioned sputum
[or bronchoalveolar lavage (BAL) fluid] from patients in the
TIC group was performed on the day when treatment of
extended-infusion imipenem/cilastatin plus tigecycline has
been instituted for 10 days.Clinical cure was defined as the disappearance of
symptoms and signs of pneumonia, with resolved pneu-
monic lesion on radiography regardless of the Ab culture
status from tracheal aspirates. Conversely, therapeutic
failure for XDR-Ab pneumonia was defined as unimproved or
worsening clinical and radiological conditions with persis-
tence of strong positivity of the sputum Ab after therapy.
Microbiological eradication of the tracheal XDR-Ab was
defined as the disappearance of Ab in follow-up cultures
from bronchial aspirate (or BAL fluid) after a given treat-
ment course. Immunosuppression was defined as the pa-
tient who has actively metastatic cancer(s) or who received
one dose or more of chemotherapy or other immunosup-
pressant(s) within the past 1 month, or  14 days of
corticosteroid at an equivalent daily dose of  15 mg
prednisolone. In addition, acute renal failure was defined
as  50% increase in baseline serum creatinine concentra-
tion, and/or requirement of renal replacement therapy.20
The condition of acute respiratory distress syndrome was
as defined elsewhere.21
As compared to each TIC case, we retrospectively looked
for VAP cases (1:2) accompanied with pneumonic (VAP)
XDR-Ab bacteremia who have matched scoring points (i.e.,
difference of a total score  3 points; the matching pro-
tocol and scoring variables were modified from those pre-
viously described by Pittet et al22) and received
sulbactameimipenem/cilastatin therapy throughout the
course during 2013. These patients comprised the SIC
group. In our survey, we established the matching variables
between the TIC and SIC groups as follows: age (0 point if
the age difference was < 5 years, 1 point if the age dif-
ference was 5e10 years, and 2 points if the age difference
was >10 years), sex (0 point if the same, otherwise was 1
point), Charlson index score (0 point if the score difference
was  2, 1 point if the difference ranged from 3 to 5, and 2
points if the score difference was > 5), length of hospital
stay prior to the acquisition of XDR-Ab bacteremia (1 point
if the difference in duration was > 20% of that for the
potentially matched patient, otherwise was 0 point), as
well as Pitt bacteremia score (0 point if the score differ-
ence was  2, 1 point if the score difference ranged from 3
to 4, and 2 points if the score difference was  5).
The end point of this study was the comparison of the
30-day outcome between both patient groups. The inde-
pendent predictors of Day 30 in-hospital case fatality were
explored using statistics (see following). In addition, the
adverse events relevant to tigecyclineeimipenem/cil-
astatin therapy for the TIC group were also recorded. This
clinical study was approved by the Institutional Review
Board of Wan Fang Hospital, Taipei Medical University,
Taipei, Taiwan.Bacteriological identification and antimicrobial
susceptibility testing
The Ab complex isolates (from blood, tracheal aspirate, and
BAL fluid) were presumptively identified by colony
morphology, Gram staining, growth at 37C, negative oxi-
dase, and oxidation of glucose. The Phoenix PMIC/ID-30
bacterial identification system (Becton-Dickinson Diag-
nostic Instrument Systems, Sparks, MD, USA) was then used
TIC versus VAP due to XDR Acinetobacter baumannii 927to confirm the identity of these isolates. Genospecies of
Acinetobacter spp. collected from the blood specimens of
both groups of patients were validated in accordance with
the intergenic spacer region of 16Se23S ribosomal RNA
gene, as previously described.23
The susceptibility to and MICs of imipenem as well as
ampicillin/sulbactam were determined for the bloodstream
XDR-Ab isolates collected from both groups of patients
using the agar dilution method in accordance with the MIC
breakpoints recommended by the Clinical and Laboratory
Standards Institute in 2013.24 Following inoculation with 104
colony-forming units (CFU) of Ab onto MuellereHinton agar,
which contains a series of 2-fold dilution of imipenem, the
agar plates were then incubated at 35C in 5% CO2 for
18e20 hours. The MICs of tigecycline were determined with
the broth microdilution method in accordance with the
Clinical and Laboratory Standards Institute guidelines.24
The concentrations of the antimicrobials under evaluation
against the bloodstream XDR-Ab isolates ranged from
0.06 mg/mL to 128 mg/mL. To avoid degradation, solutions
of tigecycline were freshly prepared on the day of the ex-
periments. Susceptibility to tigecycline (with MIC  2 mg/
mL being classified within the susceptible category) was
interpreted as per the United States Food and Drug
Administration recommendation for Enterobacteriaceae
spp.25 The antimicrobial nonsusceptibility pattern of Ab
from tracheal aspirate or BAL fluid should be grossly in
agreement with that of the bloodstream Ab isolate for each
TIC and SIC participant. Pseudomonas aeruginosa
ATCC27853 and Escherichia coli ATCC 25922 were applied as
the internal control for each test run.Analysis of carbapenem resistance genes
Extraction and purification of DNA from the bloodstream
XDR-Ab isolates of patients in the TIC and SIC groups were
carried out as previously described.23 The primers used in
this study are listed elsewhere.26 Metallo-b-lactamase
genes, blaIMP and blaVIM, as well as carbapenem hydrolyzing
Class D b-lactamase genes, including blaOXA-51-like, blaOXA-
58-like, blaOXA-23-like, and blaOXA-24-like genes, were
detected using the polymerase chain reaction (PCR)
method.27Checkerboard titration analysis
To understand the in vitro synergism of the tigecycline-
eimipenem scheme against the XDR-Ab isolates collected
from patients in the TIC group, the checkerboard titration
method was applied to assess the activity of this anti-
bioticcombination.12 Test tubes containing imipenem or
tigecycline in MuellereHinton broth were prepared in a
checkerboard configuration in 96-well plates, as described
by Sheng et al.28 The fractional inhibitory concentration
(FIC) index for tigecyclineeimipenem combination was
calculated by dividing the concentration of that drug
necessary to inhibit growth in a given row by the MIC of the
agent alone. The FIC index (FICI) was obtained by summing
the separate FIC of respective agents. Interpretation of the
FICI was as follows: FICI  0.5, synergy; FICI > 0.5 and  1,additivity; FICI >1 and  4, indifference; and FICI > 4.0,
antagonism.
Time-kill analysis
The XDR-Ab bacteremic isolates from TIC patients were
also submitted to the time-kill analysis, as described
previously.17 Because the maximal serum concentration of
imipenem for healthy individuals ranged from 30 mg/mL to
35 mg/mL,29 which would be prominently compromised for
critically ill patients,30 imipenem was added with the
fixed concentration of 16 mg/mL and tigecycline was
added at the concentration of 0.5  MIC (subinhibitory
concentration). Control experiments lacking active anti-
microbial drugs (i.e., the bacterial growth curve) were
also conducted simultaneously in this time-kill analysis.
Synergy of the imipenemetigecycline combination was
defined as a > 2 log10 decrease in CFU/mL when
compared with the more active constituent of these two
drugs.
Pulsed-field gel electrophoresis
To delineate the genetic relatedness of the bloodstream Ab
isolates collected from the TIC group cases, we picked up
those pure overnight-cultured Ab colonies to perform the
pulsed-field gel electrophoresis (PFGE) analysis. Briefly,
after digestion with SmaI (New England BioLabs, Beverly,
MA, USA), the DNA fragments were subjected to PFGE in 1%
agarose gel (BioLab Laboratories, Hercules, CA, USA) in
0.5 TriseborateeEDTA buffer (0.089 mmol/L boric acid,
2 mmol/L EDTA). The gels were stained with ethidium
bromide and then were photographed with UV light. The
interpretation of banding patterns of electrophoresis was
carried out visually in accordance with the criteria pro-
posed by Bannerman et al.31
Statistical analyses
The continuous variables were presented as the mean with
standard deviation or median with ranges, and were
compared using the Student t test or ManneWhitney U test,
depending on the validity of normality assumption. The
categorical variables were expressed as percentages of the
total number of patients analyzed, and were compared
using the Chi-square test or Fisher’s exact test as appro-
priate. To investigate the independent predictors regarding
Day 30 mortality of VAP patients with XDR-Ab pneumonic
bacteremia, variables with p < 0.1 between nonsurvivors
and survivors in the univariate analysis were further
analyzed using the multivariate logistic regression method.
In addition, we also used KaplaneMeier survival curves to
explore the difference in cumulative survival rates between
TIC and SIC patients (censoring dead participants at the
time of death; otherwise, patients were considered sur-
viving cases if they were still alive by Day 30 after the XDR-
Ab bacteremia), and applied the log-rank test to compare
the survival rates of patients between the two groups. All
statistical analyses were performed using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA).
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Clinical characteristics and outcome of patients
In this study, we collected a total of 28 TIC and 56 SIC cases
with VAP and concomitantly pneumonic XDR-Ab bacter-
emia. The demographic characteristics, comorbidities,
various hospital exposure factors prior to XDR-Ab VAP
bacteremia, as well as the percentages of the presence of
blaOXA-23-like genes in the bloodstream XDR-Ab strains be-
tween the two patient groups were comparable (Table 1).
All of these patients have received broad-spectrum antibi-
otic(s) prior to acquiring the XDR-Ab VAP bacteremia.
Among the 28 TIC group cases, two also had urinary tract
infection due to Candida albicans, and the other two cases
had concomitant catheter-associated fungemia due to
Candida parapsilosis. These four patients were copre-
scribed with appropriate antifungal antibiotics, and theTable 1 Comparisons of baseline demographic characteristics
ventilator-associated pneumonia with associated pneumonic XD
polymerase chain reaction used in detecting the carbapenema
strains.a
Characteristics TIC group (n Z
Age (y) 75 (45e88)
Male sex 16 (57.1)
Underlying disorders
Malignancy 6 (21.4)
Cardiovascular diseases 2 (7.1)
Diabetes mellitus 16 (57.1)
Hepatic diseases 2 (7.1)
Renal diseases 6 (21.4)
Pulmonary diseases 6 (21.4)
Neurologic diseases 6 (21.4)
Charlson comorbidity index 2 (1e8)
WBC count (103/mL) 16 (1.55e29.8
Shock 16 (57.1)
APACHE II score 30 (19e45)
Pitt bacteremia score 7 (4e14)
CPIS 7 (4e10)
PaO2/FiO2 189 (105e279)
Hospital exposure factors, prior to the XDR-Ab VAP bacteremia
Immunosuppression 12 (42.9)
Prior stay at healthcare setting(s) 26 (92.9)
Length of hospital stay (d) 12 (6e17)
Length of ventilator use (d) 9 (4e13)
Usage of the central venous lines (No.-day) 7 (2e16)
Use of the urinary catheter 28 (100)
Recent surgery 14 (50.0)
PCR for investigating the genes encoding for carbapenemase in b
Presence of the blaOXA-23-like genes 4 (14.3)
a All bloodstream XDR-A. baumannii isolates from patients belong
detected by PCR method, whereas the blaIMP and blaVIM genes were n
Data are presented as n (%) or median (range), unless otherwise indi
Ab Z Acinetobacter baumannii; APACHE IIZ Acute Physiology and
CPIS Z clinical pulmonary infection score; PaO2/FiO2 Z ratio of pati
from the ventilator; ORZ odds ratio; PCRZ polymerase chain reacti
plus extended-infusion imipenem/cilastatin; VAPZ ventilator-associa
resistant.central venous catheters of the latter two cases were
rapidly removed. Later, their fungal infections resolved
without sequelae. In addition, four patients developed
vomiting, and the other two patients have skin eruptions
during the tigecyclineeimipenem/cilastatin therapy
course. However, these minor adverse events could be
relieved by medication.
Four TIC patients died from breakthrough primary
bacteremia (3 had Burkholderia cepacia bacteremia and 1
had the imipenem-resistant P. aeruginosa bacteremia) prior
to Day 30 of the XDR-Ab VAP bacteremia (see the following
Discussion). By contrast, in the SIC group, there were 36
case fatalities, of whom 24 patients and eight patients died
because of breakthrough XDR-Ab and methicillin-resistant
Staphylococcus aureus bacteremia, respectively.
Compared to the SIC group cases, the outcome of TIC cases
appeared to be statistically much better [surviving case
number, 24 (85.7%) vs. 20 (35.7%); p Z 0.007]. The, comorbidities, hospital exposure factors for patients with
R Acinetobacter baumannii bacteremia, and the results of
se-encoding genes for the bloodstream XDR-A. baumannii
28) SIC group (n Z 56) OR 95% CI p
77 (40e86) 0.78
28 (50) 1.33 0.53e3.32 0.54
16 (28.6) 0.68 0.23e1.99 0.48
8 (14.3) 0.46 0.09e2.34 0.35
28 (50.0) 1.33 0.53e3.32 0.54
12 (21.4) 0.28 0.06e1.30 0.12
20 (35.7) 0.49 0.17e1.41 0.19
16 (28.6) 0.68 0.23e1.99 0.48
24 (42.9) 0.36 0.13e1.04 0.08
2 (1e8) 0.89
) 15.4 (2.42e26.7) 0.79
28 (50.0) 1.33 0.53e3.32 0.54
29 (20e45) 0.94
8 (4e14) 0.85
7 (4e9) 0.73
183 (101e275) 0.69
28 (50.0) 0.75 0.30e1.87 0.54
50 (89.3) 1.56 0.29e8.28 0.60
11 (6e16) 0.77
8 (4e12) 0.85
8 (3e13) 0.93
56 (100) 1.00 1.00
36 (64.3) 0.56 0.22e1.40 0.21
loodstream XDR-Ab strains
12 (21.4) 0.61 0.18e2.10 0.44
ing to the TIC and SIC groups have blaOXA-51-like genetic traits
ot detected on any of the XDR-A. baumannii strains analyzed.
cated.
Chronic Health Evaluation II score; CI Z confidence interval;
ent’s arterial partial O2 pressure to the fraction of inspiratory O2
on; SICZ sulbactam plus imipenem/cilastatin; TICZ tigecycline
ted pneumonia; WBCZ white blood cell; XDRZ extensively drug-
TIC versus VAP due to XDR Acinetobacter baumannii 929KaplaneMeier curves with regard to the cumulative survival
rates for two patient groups are presented in Figure 1. A
significantly higher cumulative survival rate was observed
for the TIC case group than for the SIC group with a sta-
tistically significant difference (p < 0.001, by log-rank
test).
MIC data against XDR-Ab isolates, and follow-up
microbiological results
For both patient groups, all XDR-Ab isolates collected from
the tracheal aspirate and blood culture samples showed
resistance to all antibiotics routinely investigated. More-
over, 18 (64.3%) bloodstream XDR-Ab isolates from the TIC
group have a tigecycline MIC of 2 mg/mL, with the
remaining 10 isolates falling within the nonsusceptible
category. By contrast, the imipenem MIC values of these
bacteremic XDR-Ab strains ranged from 16 mg/mL to
128 mg/mL. The MIC50/MIC90 values of these bloodstream
XDR-Ab isolates against imipenem and tigecycline were 32/
64 mg/mL and 2/8 mg/mL, respectively. Of note, the dif-
ferences in MIC levels to imipenem, tigecycline, and
ampicillin/sulbactam for the bacteremic XDR-Ab isolates
between the two groups were not significant when the
ManneWhitney U analysis was used.
With respect to the follow-up sputum microbiological
survey, we observed that 20 (71.4%) patients of the TIC
group still had XDR-Ab isolates cultured from tracheal
aspirate samples after the 10-day tigecyclineeimipenem/
cilastatin therapy. Nevertheless, among these 20 TIC cases
with XDR-Ab persisting in sputum after treatment, only fourFigure 1. KaplaneMeier survival curves regarding comparison o
having ventilator-associated pneumonia with pneumonic XDR-Acine
regimen of either tigecycline plus extended-infusion imipenem
tameimipenem/cilastatin therapy (solid line), or treated with th
throughout the course (broken line). XDR Z extensively drug-resispatients diedd17 days (Patient 12), 19 days (Patient 15), 20
days (Patient 7), and 22 days (Patient 13), respectively,
after the therapy consisting of tigecycline plus extended-
infusion imipenem/cilastatin was initiated. It is noteworthy
that the blood cultures grew monomicrobial B. cepacia
(from Patients 7, 12, and 15) or P. aeruginosa (from Patient
13) but not from their subsequent sputum samples prior to
the fatality of these four TIC cases. Finally, in the analysis
of in-hospital fatality for VAP patients by multivariate lo-
gistic regression, we found that development of break-
through bacteremic episodes [odds ratio (OR), > 103; 95%
confidence interval (CI), 4.97e>105; p Z 0.026], use of
sulbactameimipenem/cilastatin throughout the course (OR
8.56; 95% CI, 2.81e29.75; pZ 0.002), as well as shock (OR,
2.67; 95% CI, 1.34e7.98; p Z 0.02) were the independent
predictors for Day 30 mortality (Table 2).
Data of the in vitro synergy tests and PCR study
In accordance with the checkerboard titration data against
the 28 bloodstream XDR-Ab isolates collected from the TIC
cases, with the exception of four isolates (from Patients 7,
12, 13, and 15, all of whom died prior to Day 30) showing
indifference results, the remaining isolates exhibited re-
sults of in vitro synergism (nZ 12) or additivity (nZ 12) for
the tigecyclineeimipenem combination. The 12 XDR-Ab
isolates showed synergism at concentrations ranging from
0.0625  MIC to 0.125  MIC of imipenem plus from
0.0625  MIC to 0.125  MIC of tigecycline. Additionally,
the other 12 XDR-Ab isolates exhibited additivity at con-
centrations that ranged from 0.125  MIC to 0.5  MIC off the cumulative survival rates between two patient groups
tobacter baumannii bacteremia treated by either the salvage
/cilastatin following failure of responding to 3-day sulbac-
e regimen consisting of sulbactam plus imipenem/cilastatin
tant.
Table 2 Comparisons of various characteristics, including (1) age, sex, the underlying disorders as well as Charlson comor-
bidity index of enrolled patients; (2) physiologic condition or index at the day when the extensively drug-resistant (XDR) Aci-
netobacter baumannii bacteremia due to ventilator-associated pneumonia (VAP) occurred; (3) hospital exposure factors before
the enrolled patient(s) acquired XDR-A. baumannii VAP bacteremia; and (4) other major events that happened after XDR-A.
baumannii VAP bacteremia, between nonsurvivors and survivors (Day 30).a
Characteristics Nonsurvivors
(n Z 40)
Survivors
(n Z 44)
Univariate analysis Multivariate analysis
OR (95% CI) p* OR (95% CI) p*
Age (y) 60 (40e83) 64 (48e88) 0.69
Male sex 26 (65) 18 (40.9) 2.68 (1.11e6.49) 0.03 1.84 (0.94e4.52) 0.11
Underlying disorders
Malignancy 12 (30) 10 (22.7) 1.46 (0.55e3.87) 0.45
Cardiovascular diseases 8 (20) 2 (4.5) 6.75 (1.35e33.77) 0.02 4.78 (0.93e28.45) 0.09
Diabetes mellitus 20 (50) 24 (54.5) 0.83 (0.35e1.97) 0.68
Hepatic diseases 8 (20) 6 (13.6) 1.58 (0.50e5.04) 0.44
Renal diseases 16 (40) 10 (22.7) 2.27 (0.88e5.85) 0.09 1.63 (0.69e3.97) 0.16
Pulmonary diseases 14 (35) 8 (18.2) 2.42 (0.89e6.62) 0.08 1.69 (0.76e5.14) 0.14
Neurologic diseases 20 (50) 10 (22.7) 3.40 (1.33e8.69) 0.01 1.98 (0.96e6.84) 0.07
Charlson comorbidity index 3 (1e6) 4 (2e8) 0.58
Physiologic condition/index, at the day when patient(s) acquired the XDR-Ab VAP bacteremia
WBC count (103/mL) 14.5 (1.55e24.3) 15.7 (2.42e29.8) 0.79
Shock 28 (70) 16 (36.4) 4.08 (1.64e10.18) 0.003 2.67 (1.34e7.98) 0.02
APACHE II score 29 (19e45) 31 (22e41) 0.74
Pitt bacteremia score 10 (5e14) 8 (4e10) 0.31
CPIS 7 (5e10) 6 (4e9) 0.49
PaO2/FiO2 196 (112e274) 188 (101e279) 0.65
Hospital exposure factors, before patient(s) acquired XDR-Ab VAP bacteremia
Length of hospital stay (d) 10 (7e14) 11 (6e17) 0.55
Length of ventilator use (d) 9 (6e13) 7 (4e11) 0.25
Immunosuppression 26 (65) 14 (31.8) 3.68 (1.34e9.87) 0.04 2.57 (0.95e7.28) 0.07
Usage of central venous
lines, No.-day
11 (5e15) 10 (2e16) 0.39
Surgery 28 (70) 22 (50) 2.33 (0.89e5.72) 0.07 1.74 (0.77e4.28) 0.14
Other major events, after patient(s) acquired XDR-Ab VAP bacteremia
Acute renal failure 22 (55.0) 20 (45.4) 1.47 (0.62e3.47) 0.38
Acute respiratory distress
syndrome
10 (25) 14 (31.8) 0.71 (0.27e1.86) 0.49
New cardiovascular insults 4 (10) 8 (18.1) 0.50 (0.14e1.81) 0.29
Breakthrough bacteremic
episode
36 (90) 0 (0) 3950 (7.33e>106) 0.01 2655 (4.97e>105) 0.026
Treatment by sulbactam
eimipenem/cilastatin
throughout the course of
XDR-Ab VAP bacteremia
36 (90) 20 (45.4) 10.8 (3.28e35.55) <0.001 8.56 (2.81e29.75) 0.002
a PaO2/FiO2 denotes the ratio of patient’s arterial oxygen pressure to the fraction of inspiratory oxygen from ventilator. Acute renal
failure was defined as previously described. Acute respiratory distress syndrome was defined as elsewhere. New cardiovascular insults
included new-onset cerebrovascular accident, acute myocardial infarction, congestive heart failure, and dissecting aortic aneurysm.
Data are presented as n (%) or median (range), unless otherwise indicated.
*The factor with p < 0.1 by the univariate analysis would enter into the multivariate statistical analysis of logistic regression.
Ab Z Acinetobacter baumannii; APACHE IIZ Acute Physiology and Chronic Health Evaluation II; CI Z confidence interval;
CPIS Z clinical pulmonary infection score; OR Z odds ratio; WBC Z white blood cell.
930 S.-S. Jean et al.imipenem plus from 0.125  MIC to 0.5  MIC of tigecycline.
The time-kill kinetic analysis regarding all bloodstream
XDR-Ab isolates (from patients in the TIC group) against
tigecyclineeimipenem revealed that this combination
scheme also displayed good synergistic effect on all but
four XDR-Ab isolates collected from Patients 7, 12, 13, and
15 (Figure 2). The MIC values against imipenem/tigecycline
for the XDR-Ab isolates obtained from Patients 7 and 13 aswell as Patients 12 and 15 were 128/8 mg/mL and 64/8 mg/
mL, respectively. The molecular characterization revealed
that all bloodstream XDR-Ab isolates have blaOXA-51-like
genes, whereas 16 isolates (four from Patients 7, 12, 13,
and 15 of the TIC group, and the remaining 12 isolates from
the SIC group) coharbored blaOXA-23-like genes. No blaIMP or
blaVIM genes were detected in any bloodstream XDR-Ab
strain by PCR assay in both groups.
Figure 2. The time-kill curves of tigecycline (at the concentration of 0.5  MIC) plus imipenem (at a fixed concentration of
16 mg/mL) against bloodstream XDR-Acinetobacter baumannii isolates that were collected from Patients (Pt) 7, 12, 13, and 15 of
the tigecyclineeimipenem/cilastatin treatment group. The curves of control Pt 7, 12, 13, 15 isolates were those not treated with
any antimicrobial agent. MIC Z minimum inhibitory concentration; XDR Z extensively drug-resistant.
TIC versus VAP due to XDR Acinetobacter baumannii 931PFGE data
The analysis of PFGE regarding 28 bacteremic XDR-Ab
strains from the TIC group showed a high degree of ge-
netic diversity except those collected from Patients 17e20
and Patients 22e25 (figure not shown). These two XDR-Ab
pairs have concordant MIC levels to imipenem and tigecy-
cline, respectively.Discussion
In this survey, on the basis of the attending physician’s
judgment, we set 3 days as the cutoff duration to decide
the change in the therapeutic antibiotic regimen for pa-
tients with XDR-Ab VAP bacteremia if their family agreed
with our suggestion. In this study, we demonstrated that
the salvage regimen, consisting of tigecycline plus pro-
longed (3 hours) infusion standard-dose imipenem/cil-
astatin, showed good clinical efficacy on VAP patients with
XDR-Ab VAP bacteremia refractory to imipenem/cilastatin
plus sulbactam. In addition, the molecular characterization
revealed that four bloodstream XDR-Ab isolates (from pa-
tients in the TIC group) coharboring the blaOXA-23-like genes
have significantly high imipenem MIC levels, consistent with
a prior investigation.32 Although a recent prospective study
pertaining to hospital-acquired infections due to MDR-Ab
also revealed that patients treated with a tigecycline-
containing antimicrobial regimen would have more favor-
able outcomes than those treated by other drug(s),33 this
study targeted Ab isolates in vitro susceptible to
tigecycline.
From the pharmacokinetic (PK) study, remarkably low
tigecycline concentrations (0.01e0.02 mg/mL) in ELF werefound in three VAP patients using the BAL analysis.34 In
addition, VAP patients were also noted to have promi-
nently poorer pharmacodynamic (PD) data [lower area
under-the-concentration (AUC) at a time of 0 hours to 24
hours (fAUC0e24), and mean AUC] for tigecycline than
those without VAP.35 Furthermore, in terms of clinical and
microbiological responses, the tigecycline MICs > 1.0 mg/
mL for VAP pathogens were verified to exert a detrimental
impact on the ratio of fAUC0e24 to MIC, well correlating
with poor survival rates in critically ill patients.36 Although
these disadvantageous data relevant to tigecycline’s effi-
cacy on VAP treatment existed, tigecycline monotherapy
with 100 mg administered intravenously every 12 hours has
recently been shown to achieve much more favorable
outcomes for patients with NP than those of NP patients
treated with imipenem at a dosage of 1 g every 8 hours.37
Hence, underestimation of tigecycline’s efficacy on VAP
might exist when prior PK/PD data were applied.34,35,38
Despite the fact that tigecycline MIC levels against all of
our VAP-Ab isolates were  2 mg/mL, the tigecycline-
eimipenem/cilastatin scheme apparently exerts good
clinical efficacy for these VAP patients. This finding agrees
with a previous in vitro study that addressed the fact that
significant synergism would emerge on XDR-Ab strains
when tigecycline was combined with imipenem or
amikacin.39
In our study, the high (71.4%) rate of XDR-Ab persistence
within the lower respiratory tract after a 9-day therapy of
tigecycline plus extended-infusion imipenem/cilastatin
posed a stark contrast to the low (14.3%) rate of Day 30
case-fatality for VAP patients with pneumonic XDR-Ab
bacteremia (with tigecycline MICs ranging from 2 mg/mL
to 8 mg/mL; p Z 0.002). This finding differs from that of a
previousinvestigation.40 Among the three VAP patients also
932 S.-S. Jean et al.with XDR-Ab bacteremia (of which tigecycline’s MICs ranged
from 1 mg/mL to 8 mg/mL) in that study, two (67%) patients
with microbial eradication in sputum had favorable out-
comes (cure) after undergoing tigecycline plus imipenem/
cilastatin therapy.40 The other notable finding is that B.
cepacia emerged as the main organism of breakthrough
bacteremic episodes after tigecyclineeimipenem/cil-
astatin salvage therapy against VAP due to XDR-Ab isolates,
in marked contrast to that described for patients receiving
tigecycline treatment.41 It is not surprising because B.
cepacia are mostly in vitro nonsusceptible to tigecycline
and imipenem/cilastatin.5
The checkerboard MIC analysis, a method of controver-
sial reproducibility, was considered to underestimate the
synergistic potential against nonfermentative GNB as
compared with the time-kill study.42 In our study, tigecy-
cline plus imipenem exhibits in vitro synergism or additivity
against most (24/28,85.7%) of the bloodstream XDR-Ab
isolates by the checkerboard MIC test, which might indi-
rectly denote that synergism of this combination regimen
against these Ab isolates would be seen in the time-kill
analysis.
There are several limitations in our study. First, although
we demonstrated that the efficacy of tigecycline plus
extended-infusion imipenem/cilastatin against the XDR-Ab
VAP bacteremia is good clinically, our nonrandomized
single-hospital series virtually only collected a small num-
ber of VAP cases. Hence, we might fail to explore other
independent predictors about 30-day case fatality, and the
success of this combination scheme might not be general-
ized into those of the worldwide VAP in relation to XDR-Ab.
Second, we did not perform the clonality test to exclude
the dissemination of XDR-Ab clone(s) between patients in
the SIC group. Third, considerable variations in the AUC and
fAUC0e24/MIC ratio existed among patients with VAP, as
described elsewhere.8,35 Because the measurement of
these PK/PD parameters was not included in the design of
present study, we could not correlate the patient’s
outcome with these parameters. Fourth, we did not
perform the time-kill analyses against ampicillin/sulbactam
plus imipenem for the bloodstream XDR-Ab isolates
collected from TIC cases, as performed by Hsueh et al.7
However, sulbactam would not provide the synergistic ef-
fect with meropenem against GNB when the meropenem
MIC level is > 8 mg/mL.43 All analyzed Ab isolates have
imipenem MICs > 8 mg/mL, which possibly predicts poor
in vitro activity of the imipenemesulbactam regimen in our
XDR-Ab.
In conclusion, the present survey demonstrates that
prolonged-infusion imipenem in conjunction with subin-
hibitory concentration of tigecycline could achieve good
clinical efficacy in VAP patients with pneumonic XDR-Ab
bacteremia. Additionally, the in vitro data of synergism or
additivity obtained with the checkerboard titration analysis
of tigecyclineeimipenem against these XDR-Ab isolates are
well correlated with 30-day in-hospital survival outcome.
However, this combination scheme is not effective for four
patients infected by XDR-Ab isolates with high imipenem
and tigecycline MIC values. Large-scale investigations
focusing on the outcomes of similar VAP patients treated by
tigecycline plus extended-infusion imipenem/cilastatin are
warranted in the future.Conflicts of interest
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